Non-Muscle Invasive Bladder Cancer VL

The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz

Details
Richard Matulewicz joins Ashish Kamat presenting findings on the association of smoking status on recurrence of non-muscle invasive bladder cancer (NMIBC) in a contemporary cohort of patients with predominantly high-risk, recurrent NMIBC managed with photodynamic enhanced cystoscopy. A retrospective study was conducted in a multi-institutional registry. Smoking has a strong causal association with...

Novel Immune Checkpoint Axis To Understand BCG Resistance and Improve Treatment in Non-muscle Invasive Bladder Cancer - Amir Horowitz & John Sfakianos

Details
John Sfakianos and Amir Horowitz join Ashish Kamat discussing a novel immune checkpoint axis in non-muscle-invasive bladder cancer, specifically looking at the HLA-E and NKG2A axis in non-muscle invasive bladder cancer, as it relates to Bacillus Calmette-Guerin (BCG) and BCG resistance. Biographies: Amir Horowitz, Ph.D., is an Assistant Professor of Oncological Sciences and a member of the Precisi...

Conundrums in Bacillus Calmette Guerin (BCG) Unresponsive Nonmuscle Invasive Bladder Cancer Trials - Roger Li

Details
Joining Ashish Kamat from the Moffit Cancer Center in Tampa, Florida is Roger Li to dive into all things BCG unresponsive bladder cancer. Dr. Li shares what is known about BCG unresponsive disease, some of the conundrums that clinicians and the FDA are challenged by when evaluating and designing clinical trials in this area, and answers a series of questions from Dr. Kamat covering many topics in...

Combining BCG and Intravesical Gemcitabine (GBIG) for Patients with BCG-Relapsing High-Grade NMIBC Cancer A Phase 1/2 Trial- Eugene Pietzak

Details
Eugene Pietzak, MD joins Ashish Kamat, MD MBBS, to discuss an investigator-initiated trial, "Combination BCG and Intravesical Gemcitabine (CBIG) in Patients with BCG Relapsing Non-Muscle Invasive Bladder Cancer" (NCT04179162) that is currently recruiting. Dr. Pietzak explains the rationale for the trial design and the background on the questions this trial seeks to understand, in the combination o...

The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker

Details
Yair Lotan, MD, and Daniel Parker, MD join Ashish Kamat, MD, MBBS in a discussion on the efficacy and utilization of Blue Light Cystoscopy (BLC) Cysview® (hexaminolevulinate HCl). Dr. Lotanoffers his perspective on the use of blue light cystoscopy in bladder cancer detection in the hospital and Dr. Parker offers his perspective on the use in the office. Studies have shown that BLC improves the det...

Improved Tumor Visibility, Detection Rate and Reduced Recurrence Rates After TURBT - Siamak Daneshmand and Marek Babjuk

Details
Siamak Daneshmand and Marek Babjuk join Ashish Kamat in this conversation on improving tumor detection through improved visibility and reducing recurrence rates of bladder cancer. Siamak Daneshmand offers his perspective on the use of Blue Light Cystoscopy (BLC®) with Cysview® for improving detection and reduced recurrence of bladder cancer. Marek Babjuk presents his perspective on the use of phot...

Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak

Details
Subtypes in non-muscle-invasive bladder cancer are not well-defined, whereas the molecular landscape of muscle-invasive bladder cancer is relatively well-established. During the optimizing personalized management of non-muscle-invasive bladder cancer session at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Eugene Pietzak, MD, discussed the molecular landscape...

Trained Immunity as a Molecular Mechanism for BCG Immunotherapy - Sita Vermeulen

Details
In this conversation with Ashish Kamat, Sita Vermeulen details a perspective recently published in Nature Reviews Urology on trained immunity as a molecular mechanism for Bacillus Calmette-Guerin or BCG immunotherapy in bladder cancer. BCG is the gold standard adjuvant therapy for high-risk nonmuscle-invasive bladder cancer (NMIBC). One of the aspects of innate immunity that has not been a topic o...

Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni

Details
The Phase 3 data from the United States clinical trial evaluating an investigational gene therapy, nadofaragene firadenovec (rAd-IFN/Syn3), for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) was recently published in The Lancet Oncology. In this conversation with Dr. Ashish Kamat, Girish Kulkarni, MD discusses the k...

How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black

Details
Co-chair of the Bacillus Calmette Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer session during the 2020 Virtual Bladder Cancer Advocacy Network Think Tank (BCANTT) meeting, Peter Black, MD joins Ashish Kamat, MD, MBBS providing a succinct overview of this session highlighting the clinical and the translational panel which addresses defining treatment failure after BCG treatment for...
email news signup